Prior Recreational Cannabis Use Strongest Predictor of Willingness to Join Medical Cannabis Trials | Research

The takeaway

Among 250 patients with inflammatory rheumatic diseases, 75% expressed interest in medical cannabis clinical trials, with prior recreational cannabis use being the strongest predictor of willingness to participate — raising important questions about selection bias in cannabinoid research.

Clinical trial designers, rheumatologists, cannabinoid researchers, and pharmaceutical companies developing cannabis-based medicines.

What the researchers found

Previous recreational cannabis use was the strongest predictor of interest in medical cannabis clinical trials (OR=1.89), followed by limitations in daily activities (OR=1.08) and biologic DMARD therapy (OR=1.43). Barriers included insufficient information (67%), fear of side effects (40%), and fear of dependence (31%).

Why it matters

If recreational cannabis users self-select into medical cannabis trials, study results may not generalize to cannabis-naive patients — a critical methodological concern for the entire field of cannabinoid clinical research.

The numbers in context

N=250; 67% female; 85% medication satisfaction; 35% interested in MC trials + 41% potentially interested; recreational use OR=1.89; daily activity limitations OR=1.08; bDMARD OR=1.43; barriers: information gap 67%, side effects 40%, dependence 31%

How the study worked

Survey of 250 inflammatory rheumatic disease patients (67% female) using an innovative chatbot app (Asepha) for patient-centered data collection, assessing sociodemographic, disease, treatment, and cannabis-related factors predicting clinical trial willingness.

What this study cannot tell us

Single-center survey; convenience sample; self-reported recreational use; chatbot survey format may select tech-savvy patients; hypothetical willingness may not translate to actual enrollment; German regulatory context may not generalize.

How to read the evidence

Well-designed survey with innovative data collection and relevant clinical sample, though single-center and hypothetical willingness limit generalizability.

When this study was published

Published 2026; uses chatbot technology for data collection.

The bigger picture

This selection bias finding has implications beyond rheumatology — if cannabis-experienced individuals dominate clinical trials, the evidence base for medical cannabis may not reflect outcomes in typical patients encountering cannabis therapeutically for the first time.

Questions still open

Should medical cannabis trials stratify by prior cannabis experience? How can researchers recruit cannabis-naive patients? Does prior cannabis experience change treatment expectations or responses?

Common questions

Who volunteers for medical cannabis studies?

People who have already used recreational cannabis are nearly twice as likely to participate, which could skew research results since their experience, tolerance, and expectations differ from cannabis-naive patients.

Would rheumatology patients try medical cannabis?

About 75% of inflammatory rheumatic disease patients expressed some interest, even though 85% were satisfied with current treatment — but barriers include lack of information (67%), fear of side effects (40%), and fear of dependence (31%).

Read the original research

Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 150, 157599

View on PubMed ↗Publisher’s paper ↗

Citation

Jg, Richter; Beichert, A; Filla, T; Chehab, G; Sert, D; Aslandag, M; Distler, Jhw; Schneider, M; Frohne, I. (2026). Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 150, 157599. https://doi.org/10.1016/j.phymed.2025.157599